Veterinärmedizinische Universität Wien Forschungsinformationssystem VetDoc

Grafischer Link zur Startseite der Vetmeduni Vienna

Sexl Veronika,

Beiträge für wissenschaftliche Veranstaltungen

Vortrag

Mah, AY; Keppel, MP; Saucier, N; Sexl, V; French, AR; Cooper, MA (2018): Cox10-deficient NK cells have increased apoptosis during MCMV infection, leading to susceptibility. Immunology Meeting, Austin, TX, United States (USA), MAY 04-08, 2018. J Immunol (200), S1 168.5.

Neubauer, H; Pham, HTT; Suske, T; Spirk, K; Zahma, S; Tangermann, S; Prchal-Murphy, M; Maurer, B; Sexl, V; Valent, P; Boersma, A; Rülicke, T; Kenner, L; Moriggl, R (2018): The role of the gain-of-function STAT5BN642H mutation in the development of leukemia/lymphoma in different hematopoietic lineages. From Receptors and Kinases towards Transcriptional Regulators: Cancer Genome Landscapes and their Therapeutic Targets; MAY 6-9, 2018; Seggau, Stmk, Austria. 2018.

Porpaczy, E; Tripolt, S; Holbl-Kovacic, A; Gisslinger, B; Bago-Horvath, Z; Casanova-Hevia, E; Clappier, E; Decker, T; Fajmann, S; Fux, DA; Greiner, G; Gultekin, S; Heller, G; Herkner, H; Hormann, G [and 22 others] (2018): JAK1/2 inhibitor therapy-associated lymphomas in myelofibrosis arising from a preexisting B-cell clone. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Vienna, Austria, SEP 28 - OCT 2, 2018. Oncol Res Treat (41), S4 38-39.

Schmoellerl, J; Barbosa, I; Van der Veen, C; Eder, T; Schmidt, L; Brandstoetter, T; Maurer, B; Terlecki, S; Hormann, G; Valent, P; Jude, J; Sexl, V; Zuber, J; Grebien, F (2018): NUP98-rearranged acute myeloid leukemia expresses high levels of CDK6 and is hypersensitive to Palbociclib treatment. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Vienna, Austria, SEP 28 - OCT 2, 2018. Oncol Res Treat (41), S4 40-40.

Bellutti, F; Kollmann, K; Dolezal, M; Villunger, A; Malumbres, M; Sexl, V (2017): CDK6-p53: A non-canonical function of CDK6 in hematological malignancies. -Cell death, inflammation and cancer; JAN 10-14, 2017 ; Obergurgl, Austria.

Borst, K; Blank, P; Flindt, S; König, M; Tegtrneyer, PK; Chhatbar, C; Skerra, J; Waibler, Z; Sexl, V; Frenz, T; Kalinke, U (2017): The role of NK cell-derived interferon-gamma in anti-viral immune responses. 5th Annual Meeting of the International-Cytokine-and-Interferon-Society (ICIS), Int Cytokine & Interferon Soc, Kanazawa, JAPAN, Japan, OCT 29-NOV 02, 2017. Cytokine (100) 59-60.

Greiner, G; Witzeneder, N; Berger, A; Schmetterer, K; Eisenworth, G; Schiefer, A; Roos, S; Popow-kraupp, T; Müllauer, L; Zuber, J; Sexl, V; Kenner, L; Sperr, WR; Mayerhofer, M; Valent, P; Hoermann, G (2017): ccl-2 Is A Kit D816v-dependent Modulator Of The Bone Marrow Microenvironment In Systemic Mastocytosis: Cod: T210. Euromedlab 2017 Athen, Athen, Greece, June 11-15, 2017. Clinical Chemistry and Laboratory Medicine (55) 709-709.

Prinz, D; Witalisz-Siepracka, A; Gotthardt, D; Putz, EM; Prchal-Murphy, M; Sexl, V (2017): NKG2D: friend or foe in NK cells mediated tumor surveillance? Together one step further - Joint Symposium of 2 PhD Programs; SEPT 25-26, 2017; Vienna, Austria. 2017.

Sexl, V (2017): Targeting STAT5 In Leukemogenesis - What's New. 37th SEF National Meeting with guest society: the British Pharmacology Society, Barcelona, Spain, JUN 18–21, 2017. Basic Clin Pharmacol (121), S2 32-32.

Sexl, V (2017): CDK6: At the interface of Rb and p53. 2nd AACR Conference on Hematologic Malignancies - Translating Discoveries to Novel Therapies, Boston, MA, United States (USA), MAY 06-09, 2017. Clin Cancer Res (23), 24 23-23.

Blatt, K; Cerny-Reiterer, S; Hölbl, A; Sadovnik, I; Herrmann, H; Herndlhofer, S; Eisenwort, G; Hauswirth, A; Hörmann, G, Willmann, M; Rülicke, T; Sill, H; Sperr, WR; Mannhalter, C; Melo, JV; Jäger, U [and 2 others] (2016): Characterization and target expression profiles of CD34+/CD38− and CD34+/CD38+ stem- and progenitor cells in acute lymphoblastic leukemia (ALL). 8346-8346.-LBG Meeting for Health Sciences; NOV 28-29, 2016; Vienna, AUSTRIA.

Edlinger, L; Berger-Bečvař, A; Hoelbl-Kovacic, A; Greiner, G; Hoermann, G; Sexl, V (2016): A PAK-STAT5 axis is key for tumor formation of BCR/ABL+ cells in vivo. -26th VetPharm Symposium; OCT 6-7, 2016; Munich, GERMANY.

Maurer, B; Nivarthi, H; Prchal-Murphy, M; Wingelhofer, B; Chen, D; Winkler, S; Schlederer, M; Pham, HTT; Kenner, L; Sexl, V; Kolbe, T; Kralovics, R; Muller, M; Rülicke, T; Moriggl, R (2016): Activated Stat5 Drives Peripheral T Cell Lymphomas. 21st Congress of the European-Hematology-Association, Copenhagen, DENMARK, JUN 09-12, 2016. Haematologica (101), S1 567-567.

Sadovnik, I; Herrmann, H; Hoelbl, A; Cerny-Reiterer, S; Warsch, W; Blatt, K; Peter, B; Hörmann, G; Eisenwort, G; Bilban, M; Sill, H; Sperr, WR; Streubel, B; Willmann, M; Rülicke, M [and 4 others] (2016): Identification of CD25 (IL-2RA) and CD26 (DPPIV) as novel markers and targets in CD34+/CD38− LSC in Ph+ CML. 8460-8460.-LBG Meeting for Health Sciences 2016; NOV 28-29, 2016; Vienna, AUSTRIA.

Sexl, V (2016): NK cells - silent killers on the move. -Translational Immunology - From Target to Therapy; OCT 28-30; Würzburg, GERMANY.

Sexl, V (2016): Targeting CDK6 - novel and surprising opportunities in hematology. -Dotan Hematological conference; SEP 11-14, 2016; Tel Aviv, ISRAEL.

Sexl, V (2016): Jak Stat Signaling in NK cells - new Players in Metastasis. Symposium of the DFG-FOR2127 "Selection and adaptation during metastatic cancer Progression"; JUNE 1-3, 2016; Regensburg, GERMANY. 2016.

Sexl, V (2016): CDK6 - Cell cycle kinase and transcriptional Regulator. Kloster Seeon Meeting PCCC; APR 29 - MAY 3, 2016; Seeon, GERMANY. 2016.

Sexl, V (2016): STATs in Nk cell mediatied tumorsurveillance. -Keystone Symposia; JAN 10-15, 2016; Colorado, USA.

Sexl, V (2016): JAK-STAT for the better or worse in NK cell biology. -16th Annual Meeting of the Society for Natural Immunity; OCT 2-5, 2016; Taormina, ITALY.

Streicher, C; Heyny, A; Andrukhova, O; Schüler, C; Kollmann, K; Kantner, I; Sexl, V; Kleiter, M; Hofbauer, LC; Kostenuik, PJ; Erben, RG (2015): Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells. -International Conference on Progress in Bone and Mineral Research 2015; DEC 03-05, 2015; Vienna, Austria.

Witalisz-Siepracka, A; Prchal-Murphy, M; Bednarik, K; Meissl, K; Putz, EM; Gotthardt, D; Sexl, V; Strobl, B; Müller, M (2015): Non-canonical TYK2 governs NK cell-mediated tumour surveillance. 3rd Annual Meeting of the International-Cytokine-and-Interferon-Society (ICIS), Bamberg, GERMANY, OCT 11-14, 2015. Cytokine (76), 1 79-79.

Berger, A; Hoelbl-Kovacic, A; Menzl, I; Kubicek, S; Moriggl, R; Gouilleux, F; Sexl, V (2014): Characterization of STAT5 serine phosphorylation as a drug target in BCR-ABL+ leukemia. -24. Vetpharm Symposium; SEP 11-12,2014; Zuerich, SWITZERLAND.

Edlinger, L; Grundschober, E; Gotthardt, D; Putz, EM; Hoelbl-Kovacic, A; Sexl, V (2014): The role of STAT5A and STAT5B in leukemia and NK cell-mediated tumor surveillance. -Cell Death, Inflammation & Immunity; NOV 30 - DEC 3, 2014; Obergurgl, AUSTRIA.

Gotthardt, D; Putz, EM; Kudweis, P; Strobl, B; Sexl, V (2014): Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. -Natural Killer Cell Symposium 2014; SEPT 10-12, 2014; Hannover, GERMANY.

Grundschober, E; Hoelbl-Kovacic, A; Bhagwat, N; Levine, R; Sexl, V (2014): Acceleration Of Bcr-Abl Plus Leukemia Induced By Deletion Of JAK2. 19th Congress of the European-Hematology-Association, Milan, ITALY, JUN 12-15, 2014. Haematologica (99), S1 794-794.

Kollmann, K; Heller, G; Schneckenleithner, C; Warsch, W; Scheicher, R; Ott, RG; Schäfer, M; Fajmann, S; Schlederer, M; Schiefer, AI; Reichart, U; Mayerhofer, M; Hoeller, C; Zöchbauer-Müller, S; Kerjaschki, D [and 9 others] (2014): A new kinase-independent function of CDK6 links the cell cycle to Tumor surveillance. Joint Symposium between Taiwan-Austrian Research Communities.; MAY 4-11, 2014; Taiwan. 2014.

Putz, EM; Leitner, NR; Müller, M; Sexl, V (2014): A novel non-canonical role of STAT1 in NK cells. -Natural Killer Cell Symposium; SEP 10-12, 2014; Hannover, GERMANY.

Sadovnik, I; Herrmann, H; Hoelbl, A; Cerny-Reiterer, S; Warsch, W; Blatt, K; Peter, B; Hoermann, G; Eisenwort, G; Bilban, M; Sill, H; Sperr, WR; Streubel, B; Willmann, M; Rülicke, T [and 4 others] (2014): Identification of CD25 (IL-2RA) and CD26 (DPPIV) as novel markers and potential targets on CD34+/CD38- LSC in Ph+ CML. -16th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy; SEP 4-7, 2014; Philadelphia, USA.

Sexl, V (2014): CDK6 - News and views. -6th International Conference on MPN; OCT 23-26, 2014; Estoril, PORTUGAL.

Sexl, V (2014): Descerning Good and Evil - JAK-STAT Signaling pathways in leukemia and immune surveillance. Life Science Meeting; SEP 24-25, 2014; Innsbruck, AUSTRIA. 2014.

Sexl, V (2014): CDK6 - new functions for an old kinase. 4th ERIA Meeting "20 Year Anniversary of the Discovery of ALK"; JUNE 20-21, 2014; Milan, Italy. 2014.

Sexl, V (2014): JAK STAT signalling in leukemia and NK cell mediated Tumor surveillance. Seminar am Georg Speyer Haus; OCT 9-10, 2014; Frankfurt, GERMANY. 2014.

Tarrio, M; Kallal, L; Sexl, V; Biron, C (2014): Signaling and function of STAT3 in NK cells during murine cytomegalovirus infection. Immunology 2014, Pittsburgh, Pa., United States (USA), MAY 2-6, 2014. J Immunol (192), S1 124.8.

Kollmann, K; Heller, G; Schneckenleithner, C; Warsch, W; Scheicher, R; Ott, R; Schäfer, M; Fajmann, S; Schlederer, M; Schiefer, AI; Reichart, U; Mayerhofer, M; Hoeller, C; Zoechbauer-Mueller, S; Kerjaschki, D [and 9 others] (2013): A new kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. -FASEB Science Research Conferences: Hematologic Malignancies; AUG 4-9, 2013; Vermont, USA.

Sadovnik, I; Herrmann, H; Cerny-Reiterer, S; Warsch, W; Blatt, K; Hoebl, A; Peter, B; Stefanzl, G; Hoermann, G; Herndlhofer, S; Streubel, B; Sperr, WR; Mannhalter, C; Sexl, V; Valent, P (2013): Evaluation of the IL-2R alpha chain (CD25) as novel marker of leukemic stem cells in Ph plus CML. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Vienna, AUSTRIA, OKT 18-22, 2013. Onkologie (36), S7 287-287.

Sexl, V (2013): Myeloproliferative Neoplasms. Kickoff Meeting - SFB F47-B20; MAR 6, 2013; Vienna, AUSTRIA. 2013.

Sexl, V (2013): A new kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. EMBO Workshop "Cycling to Death"; JAN 23-27, 2013; Obergurgl, AUSTRIA. 2013.

Sexl, V (2013): NK Cell dependent tumor surveillance - STATs in the spotlight. Immunologisches Kolloquium; Universitätsklinikum Erlangen; JAN 15, 2013; Erlangen, GERMANY. 2013.

Sexl, V (2013): Silent killers on the move - boosting NK cell activity. 3rd Austrodrugs meeting; MAR 1, 2013; Vienna, AUSTRIA. 2013.

Sexl, V (2013): The breast cancer Immune stromal interface. -IMPAKT 2013 Breast Cancer Conference; MAY 2-5, 2013; Brussels, BELGIUM.

Sexl, V (2013): Determining Druggability of STAT5 in hematopoietic Neoplasms. STAT5 Meeting; JUNE 7-8, 2013; Vienna, AUSTRIA. 2013.

Sexl, V (2013): Jaks and STATs - the good and the evil for leukemogenesis. Eight years of research at the LBI-CR; APR 14-17, 2013; Obergurgl, AUSTRIA. 2013.

Sexl, V; Berger, A; Warsch, W; Grundschober, E; Höfling, L; Moriggl, R; Hölbl-Kovacic, A (2013): Stat5 - a central player in Bcr/Abl+ leukemia. -42nd Annual Scientific Meeting, ISEH; AUG 22-25, 2013; Vienna, AUSTRIA.

Sexl, V; Berger, A; Warsch, W; Grundschober, E; Höfling, L; Moriggl, R; Hölbl-Kovacic, A (2013): Stat5 - a central player in Bcr/Abl+ leukemia. -2nd FEBS Meeting on JAK-STAT Signalling: Model Organisms and Beyond at the Albert Hall Nottingham; SEP 12-15, 2013; Nottingham, United Kingdom.

Gotthardt, D; Putz, EM; Sexl, V (2012): STATs in the Spotlight of NKCell. -European Congress of Immunology; SEPT 6-8, 2012; Glasgow, SCOTLAND. Open Access Logo

Gotthardt D., Putz E.M., Sexl V (2012): STATs in the spotlight. -NK Cell Meeting; SEP 26 - 28, 2012; Heidelberg, Germany.

Schiefer, AI; Melcher, M; Bago-Horvath, Z; Eder, S; Skrabs, C; Hauswirth, A; Streubel, B; Mannhalter, C; Stoiber, D; Sexl, V; Mullauer, L; Jaeger, U; Porpaczy, EA (2012): A New Prognostic Score for Aggressive B-Cell Lymphoma with C-MYC Translocation Integrating Clinical and Genetic Features. 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta, USA, DEC 08-11, 2012. Blood (120), 21

Sexl, V (2012): Zelluläre Signalwege – neue Angriffspunkte der Krebsbekämpfung. Antrittsvorlesung, Veterinärmedizinische Universität Wien; DEC 10, 2012; Vienna, Austria. 2012.

Sexl, V (2012): Women in science. Women in science.; JUL 07, 2012; Vienna, Austria. 2012.

Sexl, V (2012): CDK6 new funktion for an old kinase. Seminar; JUN 4, 2012; Daniel Swarovski Forschungslabor, Innsbruck, AUSTRIA. 2012.

Sexl, V (2012): Searching the Achilles heel in Bcr/Abl induced leukemia. Austrodrugs 2; MAR, 19/2012; Ce-M-M- Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, AUSTRIA. 2012.

Sexl, V (2012): JAKs and STATs in leukemia. Ludwig Boltzmann Institut für experimentelle und klinische Traumatologie; MAR 15, 2012; Wien . 2012.

Warsch, W; Grundschober, E; Gille, L; Cerny-Reiterer, S; Valent, P; Sexl, V (2012): STAT5 triggers BCR-ABL mutations by mediating ROS Production. -ESH International Conference on Myeloprobliferative Neoplasms; OKT 4 - 6, 2012; Vienna, Austria.

Kernbauer, E; Jamieson, AM; Schneckenleithner, C; Sexl, V; Reichart, U; Strobl, B; Müller, M; Decker, T (2011): Conditional ablation of Stat1 reveals the antagonistic role of interferons in the clearance of the intracellular bacterial pathogen Listeria monocytogenes. 9th Joint Meeting of the International-Cytokine-Society/International-Society-for-Interferon-and-Cytokine-Research, Florence, ITALY, OCT 09-12, 2011. Cytokine (56), 1 10-11.

Kernbauer, E; Jamieson, AM; Schneckenleithner, C; Sexl, V; Reichart, U; Strobl, B; Müller, M; Decker, T (2011): Conditional ablation of Stat1 reveals the antagonistic role of interferons in the clearance of the intracellular bacterial pathogen Listeria monocytogenes. -9th Joint Meeting of the ICS/ISICR; Okt 9-12, 2011; Florence, Italy.

Sexl, V (2011): Targeting STAT5 in CML: Mechanism-of-action of JAK2 Tyrosine Kinase Inhibitors Unmask a Direct BCR/ABL-STAT5 Axis. The JAK-STAT Pathway: 20 Years from Discovery to Drugs; Sep 22-24, 2011; Bethesda, USA. 2011.

Sexl, V (2011): Regulation and Role of STAT Molecules in Neoplastic Cells. Workshop: Mast Cell - and Mastocytosis Research; June 15, 2011; General Hospital Vienna, Austria. 2011.

Sexl, V (2011): CDK6 - an old kinase with a novel function: CDK6 in lymphoid malignancies. Seminar Düsseldorf; Dez 07, 2011; Düsseldorf, Deutschland. 2011.

Sexl, V (2011): JAKs and STATs - Key molecules for NK cell development and function. Seminar Essen; Dez 06, 2011; Essen, Deutschland. 2011.

Sexl, V (2011): Cyclin dependent kinase 6 - a novel player in NPM-ALK driven lymphoma formation. -2nd Meeting of the European Research Initiative on ALCL; June 27-28,2011; Ludwig-Boltzmann Instiute for Cancer Research (LIBI-CR), Vienna, Austria.

Sexl, V (2011): Tumor surveillance: NK Cells enter the stage. Immunity in Cancer & Allergy PhD program - Symposium ; FEB 1-3,2011; University of Salzburg; AUSTRIA. 2011.

Hantschel, OD; Eckelhart, E; Kaupe, I; Grebien, F; Wagner, KU; Sexl, V; Furga, GS (2010): Bcr Abl Directly Activates Stat5 Independent of Jak2. 52nd Annual Meeting of the American-Society-of-Hematology (ASH), Orlando, FL, DEC 04-07, 2010. Blood (116), 21 226-226.

Putz, EM; Zebedin-Brandl, EM; Prchal, M; Kovarik, P; Decker, T; Sexl, V (2010): Unexpected role of STAT1 serine727 for NK cell function. 4-4.-Annual Meeting of the Austrian Society for Allergology and Immunology (ÖGAI); DEC 3-5, 2010; Vienna, AUSTRIA.

Poster

Menzl, I; Zhang, T; Grausenburger, R; Bauer, K; Grebien, F; Valent, P; Zuber, J; Gray, N; Sexl, V (2019): CDK8 degradation – preparing the ground for mTOR inhibition in ALL. -AEK Congress 2019; Feb 27 - MAR 1, 2019; Heidelberg, Germany.

Bellutti, F; Tigan, AS; Nebenfuehr, S; Dolezal, M; Zojer, M; Grausenburger, R; Höllein, A; Neuberg, DS; Villunger, A; Kollmann, K; Sexl, V (2018): CDK6 Antagonizes p53-Induced Responses during Tumorigenesis. -FASEB Conference: Transcription, Chromatin and Epigenetis; SEP 16-21, 2018; Florence, Italy.

Maurer, B; Bellutti, F; Kollmann, K; Sexl, V; Prchal-Murphy, M (2018): Uncoupling INK proteins from CDK4/CDK6 – how do hematopoietic stem cells react? Hematopoietic Stem Cells: From the Embryo to the Aging Organism, EMBL Conference; Jun 7-9, 2018; Heidelberg, Germany. 2018.

Menzl, I; Zhang, T; Grausenburger, R; Bauer, K; Grebien, F; Kubicek, S; Valent, P; Zuber, J; Gray, N; Sexl, V (2018): CDK8 degradation - Preparing the ground for mTOR inhibition in BCR/ABL+ ALL. -23rd Congress of the European Hematogloy Association; JUNI 14-17, 2018; Stockholm, Sweden. Open Access Logo

Prchal-Murphy, M; Hoelbl-Kovacic, A; Dolezal, M; Fajmann, S; Schumich, A; Sexl, V; Dworzak, M (2018): Phospho-profiling linking AML-biology and response prediction in pediatric myeloid leukemia. 23rd Congress of EHA; JUN 14-17, 2018; Stockholm, Sweden. 2018.

Witalisz-Siepracka, A; Prinz, D; Klein, K; Leidenfrost, N; Gotthardt, D; Sexl, V (2018): JAK1 and JAK2 - the commander and the executer of NK cell function. 15th International Conference on Innate Immunity; JUNI 18-23, 2018; Chania, Kreta, Greece. 2018.

Berger, A; Edlinger, L; Menzl, I; Hoermann, G; Grundschober, E; Bago-Horvath, Z; Sexl, V; Hoelbl-Kovacic, A (2017): Maintenance of leukaemogenic potential of BCR/ABL+ cells requires PAK2 but not PAK1. -EHA European Haematology Association ; JUN 22-25, 2017; Madrid, Spain.

Doma, E; Hoelbl-Kovacic, A; Sexl, V (2017): Generation of immortal murine hematopoietic stem/progenitor cell lines from transgenic mice. -22nd Congress of EHA (EHA22); JUN 22-25, 2017; Madrid, Spain.

Doma, E; Hölbl, A; Sexl, V (2017): Generation Of Immortal Murine Hematopoietic Stem/ Progenitor Cell Lines From Transgenic Mice. 22nd Congress of the European-Hematology-Association, Madrid, SPAIN, Spain, JUN 22-25, 2017. Haematologica (102), S2 304-304. Open Access Logo

Hoelbl-Kovacic, A; Berger, A; Edlinger, L; Menzl, I; Hoermann, G; Grundschober, E; Bago-Horvath, Z; Sexl, V (2017): Maintenance Of Leukaemogenic Potential Of Bcr/Abl Plus Cells Requires Pak2 But Not Pak1 . 22nd Congress of the European-Hematology-Association, Madrid, SPAIN, Spain, JUN 22-25, 2017. Haematologica (102), S2 430-430. Open Access Logo

Maurer, B; Pham, HTT; Prchal-Murphy, M; Nivarthi, H; Wingelhofer, B; Schlederer, M; Grausenburger, R; Winkler, S; Halbritter, F; Farlik, M; Bock, C; Kenner, L; Kolbe, T; Rülicke, T; Müller, M [and 2 others] (2017): Graded STAT5A or STAT5B activity promote T-cell neoplasia. STATs: Importance In Basic & Clinical Cancer Research; Nov 15-18, 2017; Cold Spring Harbor, United States (USA). 2017.

Prchal-Murphy, M; Kollmann, K; Hoelbl-Kovacic, A; Fajmann, S; Schumich, A; Kauer, M; Sexl, V; Dworzak, M (2017): Phospho-profiling linking AML-biology and response prediction in pediatric myeloid leukemia. ESH 4th International Conference on Acute Myeloid Leukemia "Molecular and Translation": advances in biology and treatment; OCT 5-7, 2017; Estoril, Portugal. 2017.

Prinz, D; Witalisz-Siepracka, A; Gotthardt, D; Putz, EM; Prchal-Murphy, M; Sexl, V (2017): NKG2D: friend or foe in NK cell-mediated tumor surveillance? Defense is the Best Attack - Oncoimmunology Breakthroughs; OCT 9-11, 2017; Barcelona, Spain. 2017.

Tripolt, S; Hölbl-Kovacic, A; Sexl, V (2017): Lack of Stat1 predisposes to a diffuse large B-cell lymphoma-like disease. 22nd Congress of the European Hematology Association (EHA); JUN 22-25, 2017; Madrid. 2017.

Tripolt, S; Porpaczy, EA; Hoelbl-Kovacic, A; Gisslinger, B; Bago-Horvath, Z; Casanova, E; Decker, T; Fux, D; Heller, G; Herkner, H; Kolbe, T; Kornauth, C; Mueller, M; Prchal-Murphy, M; Schiefer, AI [and 14 others] (2017): JAK2-Inhibitor Therapy Associated Lymphomas in Myelofibrosis: Distinct Clinico-Pathological Features Recapitulated in a Mouse Model. 59th Annual Meeting of the American Society of Hematology; DEC 09-12,2017; Atlanta, United States (USA). 2017.

Tripolt, S; Porpaczy, EA; Hoelbl-Kovacic, A; Gisslinger, B; Bago-Horvath, Z; Casanova, E; Decker, T; Fux, DA; Heller, G; Herkner, H; Kolbe, T; Kornauth, C; Mueller, M; Prchal-Murphy, M; Schiefer, IA [and 14 others] (2017): JAK1/2-inhibitor therapy associated lymphomas in myelofibrosis: Distinct clinico-pathological features recapitulated in a mouse model. 59th ASH Annual Meeting and Exposition; DEZ 9-12,2017; Atlanta, Georgia, United States (USA). 2017.

Tripolt, S; Schneckenleithner, C; Hoelbl-Kovacic, A; Heller, G; Sexl, V (2017): Lack of Stat1 Predisposes to a Diffuse Large B-Cell Lymphoma-Like Disease. 22nd Congress of the European-Hematology-Association, Madrid, SPAIN, Spain, JUN 22-25, 2017. Haematologica (102), S2 562-562. Open Access Logo

Uras, I; Valent, P; Sexl, V (2017): Targeted Combination Therapy With Cdk4/6 Inhibitor Palbociclib In AML. 22nd Congress of the European-Hematology-Association, Madrid, SPAIN, Spain, JUN 22-25, 2017. Haematologica (102), S2 207-208. Open Access Logo

Vargas-Hernandez, A; Prchal-Murphy, M; Mace, EM; Carisey, AF; Orange, JS; Sexl, V; Forbes, LR (2017): Human STAT5B Mutations Cause Dysregulated Human Natural Killer Cell Maturation and Impaired Lytic Function. Meeting of the Latin-American-Society-for-Immunodeficiencies (LASID), Sao Paulo, Brazil, OCT 04-07, 2017. J Clin Immunol (37), S1 S2-S3.

Bellutti, F; Uras, I; Prchal-Murphy, M; Tigan, A; Rodríguez-Díez, E; Quereda, V; Malumbres, M; Sexl, V (2016): Uncoupling CDK4/6 from INK4 inhibitors – Molecular consequences for leukemogenesis. -Cellular signalling and cancer therapy; MAI 27–31, 2016 ; Cavtat, CROATIA.

Bellutti, F; Uras, ZI; Prchal-Murphy, M; Tigan, AS; Rodríguez-Díez, E; Quereda, V; Malumbres, M; Sexl, V (2016): Uncoupling CDK4/6 from INK4 inhibitors – Molecular consequences for leukemogenesis. Hematological Malignancies: from Mechanisms to Therapy; MAR 9-12, 2016; Milano, ITALY. 2016.

Didara, Z; Gotthardt, D; Putz, EM; Prchal-Murphy, M; Sexl, V (2016): CDK8 the "enemy" of NK cell cytotoxicity. NK 2016; OCT 2-5, 2016; Taormina, Italy . 2016.

Doma, E; Scheicher R, Fajmann, S; Sexl, V (2016): Generation of immortal murine hematopoietic/progenitor cell lines from trangenic mice by ectopic expression of Lhx2. -Hematopoietic Stem Cells: From the Embryo to the Aging Organism; JUNE 3-5, 2016; Heidelberg, GERMANY.

Edlinger, L; Berger-Bečvař, A; Hoelbl-Kovacic, A; Greiner, G; Hoermann, G; Sexl, V (2016): A PAK2-STAT5 axis is key for tumor formation of BCR-ABL+ cells in vivo. -OeGHO- & AHOP-Fruehjahrstagung 2016; MAR 17-19, 2016; Vienna, AUSTRIA.

Gültekin-Tigan, AS; Grausenburger, R; Bellutti, F; Scheicher, R; Prchal-Murphy, M; Schaefer, M; Barbosa, I; Muhar, M; Bock, C; Busslinger, M; Zuber, J; Sexl, V (2016): The cyclin-dependent kinase CDK6 as key regulator of the cancer epigenome. -2nd Danube Conference on Epigenetics ; OCT 5-8, 2016; Budapest, Hungary.

Meissl, K; Witalisz-Siepracka, A; Prchal-Murphy, M; Sexl, V; Müller, M; Strobl, B (2016): Cell-extrinsic STAT1 isoform-specific functions regulate NK cell maturation. -16th Annual Meeting of the Society for Natural Immunity - NK2016; OCT 3-5, 2016; Taormina, ITALY.

Prchal-Murphy, M; Putz, EM; Majoros, A; Gotthardt, D; Carotta, S; Decker, T; Sexl, V (2016): The NK cell immunological synapse – U-STAT1 at the interface of cytotoxicity. NK2016 - 16th Meeting of the Society for Natural Immunity; OCT 2-5, 2016; Taormina, ITALY. 2016.

Prinz, D; Gotthardt, D; Sexl, V (2016): Role of NKG2D on murine natural killer cells in cancer immunosurveillance. NK2016; OCT 2-5, 2016; Taormina, ITALY. 2016.

Scheicher R, Prchal-Murphy M, Sexl V (2016): CDK6 in hematopoietic and leukemic stem cells – cell cycle versus transcriptional Regulation. -Hematopoietic Stem Cells: From Embryo to the Aging Organism; JUN 2-5, 2016; Heidelberg, Germany.

Sexl, V; Gotthart, D; Putz, EM; Witalisz, A; Decker, T; Strobl, B; Müller, M (2016): AK-STAT in NK cells: For the better or worse in tumour surveillance. -Cytokine JAK-STAT Signaling in Immunity and Disease; JAN 10-14, 2016; Colorado, USA.

Wingelhofer, B; Heyes, EC; Maurer, B; Lewis, AM; Cumaraswamy, AA; Sadovnik, I; Berger-Becvar, A; Sexl, V; Valent, P; Kubicek, S; Gunning, PT; Moriggl, R (2016): Identification of a novel STAT5 inhibitor to interfere with the oncogenic activities of STAT5 in AML. 21st Congress of the European-Hematology-Association, Copenhagen, DENMARK, JUN 09-12, 2016. Haematologica (101), S1 211-211.

Witalisz-Siepracka, A; Bozovic, N; Meissl, K; Lassnig, C; Sexl, V; Müller, M; Strobl, B (2016): TYK2 regulates NK cell function by cell-intrinsic and -extrinsic mechanisms. -NK 2016 - 16th Meeting of the Society for Natural Immunity; OCT 3-5, 2016; Taormina, ITALY.

Bellutti, F; Prchal-Murphy, M; Rodriguez-Diez, E; Quereda, V; Malumbres, M; Sexl, V (2015): CDK4 and CDK6 cooperate in counteracting the INK4 family inhibitors during murine leukemogenesis. 75--EMBO EMBL Symposium: Frontiers in Stem Cells and Cancer; MAR 29-31, 2015; Heidelberg, GERMANY.

Doma, E; Grundschober, E; Hölbl-Kovacic, A; Sexl, V (2015): The role JAK2 in haematoploetic stem cells (HSCs). 98--EMBO EMBL Symposium: Frontiers in Stem Cells and Cancer; MAR 29-31, 2015; Heidelberg, GERMANY.

Edlinger, L; Prchal-Murphy, M; Gotthardt, D; Tigan, AS; Sexl, V (2015): The role of STAT5A and STAT5B in natural killer cells. -7th ÖGMBT Annual Meeting; SEP 9-11, 2015; Salzburg, AUSTRIA.

Edlinger, L; Putz, EM; Prchal-Murphy, M; Gotthardt, D; Tigan, AS; Hoelbl-Kovacic, A; Sexl, V (2015): The role of STAT5A and STAT5B in NK cells. -ÖGAI-Symposium 2015: 50 Years of B-Lymphocytes; DEC 11-12, 2015; Vienna, AUSTRIA.

Gotthardt, D; Putz, EM; Stockmann, C; Sexl, V (2015): STAT5 - the molecular switch from tumor surveillance to tumor promotion. -15th Meeting of the Society for Natural Immunity; MAY 2-6, 2015; Montebello, QUÉBEC, CANADA.

Grundschober, E; Hölbl-Kovacic, A; Sexl, V (2015): Deletion of Jak2 accelerates BCR-ABL induced leukaemia. -EMBO / EMBL Symposium: Frontiers in Stem Cells and Cancer; MAR 29-31, 2015; Heidelberg, GERMANY.

Maurer, B; Nivarthi, H; Prchal-Murphy, M; Wingelhofer, B; Chen, D; Winkler, S; Prochazkova, J; Schlederer, M; Pham, H; Loizou, JI; Kenner, L; Sexl, V; Kolbe, T; Kralovics, R; Müller, M [and 2 others] (2015): An activating STAT5 mutation is sufficient for Peripheral T Cell Lymphoma formation. 3rd Annual Meeting of the International-Cytokine-and-Interferon-Society (ICIS), Bamberg, GERMANY, OCT 11-14, 2015. Cytokine (76), 1 77-77.

Menzl, I; Berger, A; Zuber, J; Eisinger-Fux, D; Sexl, V (2015): Linking cell cycle to transcription: CDKs in BCR-ABL driven leukemia. 114--Signal Transduction Society: 19th Joint Meeting "Signal Transduction - Receptors, Mediators and Genes"; NOV 2-4, 2015; Weimar, GERMANY.

Prchal-Murphy, M; Bellutti, F; Rodríguez-Díez, E; Quereda, V; Malumbres, M; Sexl, V (2015): INK4-mediated CDK6 activity controls hematopoietic progenitor potential. 177--EMBO / EMBL Symposium: Frontiers in Stem Cells and Cancer; MAR 29-31, 2015; Heidelberg, GERMANY.

Tigan, A; Uras, I; Prchal-Murphy, M; Bago-Horvath, Z; Kudweis, P; Scheicher, R; Kollmann, K; Sexl, V (2015): Loss of CDK6 accelerates JUNB driven myeloproliferative disease and leukemia. -HEMID 2015 Meeting "Epigenetic regulation of hematopoiesis and leukemogenesis"; APR 21-22, 2015; Strassburg, FRANCE.

Uras, I; Walter, G; Bellutti, F; Prchal-Murphy, M; Scheicher, R; Tigan, A; Valent, P; Scholl, C; Fröhling, S; Sexl, V (2015): CDK6: a novel transciptional angel on the treatment of an agressive subtype of AML. -ESH International Conference on Cute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment; SEP 10-12, 2015; Budapest, HUNGARY.

Gotthardt, D; Putz, EM; Straka, E; Kudweis, P; Strobl,B; Mathias, M; Sexl, V (2014): Loss of STAT3 in Natural Killer Cells enhances NK cell dependent tumor surveillance. -10th YSA-PhD-Symposium 2014; JUN, 2014; Vienna, AUSTRIA.

Meissl, K; Klein, K; Witalisz, A; Prchal-Murphy, M; Sexl, V; Müller, M; Strobl, B (2014): STAT1 isoform specific functions in NK cell maturation and cytotoxicity. -Natural Killer Cell Symposium ; Sept 10-14, 2014; Hannover, Germany.

Putz, EM; Leitner, NR; Müller, M; Sexl, V (2014): A novel non-canonical role of STAT1 in NK cells. -6th ÖGMBT Annual Meeting ; Sept 15-18, 2014; Vienna, Austria.

Sexl, V; Putz, EM; Gotthardt, D; Strobl, B; Decker, T; Müller, M (2014): STATs in the spotlight of NK cell mediated immune surveillance. -6th ÖGMBT Annual Meeting ; Sept 15-18, 2014; Vienna, Austria.

Witalisz, A; Prchal-Murphy, M; Bednarik, K; Meissl, K; Sexl, V; Strobl, B; Müller, M (2014): Kinase-inactive Tyk2 mediates NK cell-dependent tumour surveillance and CD8+ T cell crosstalk to NK cells. -Natural Killer Cell Symposium; Sept 10-14, 2014; Hannover, Germany.

Gotthardt, D; Putz, EM; Kudweis, P; Strobl, B; Sexl, V (2013): The Role of Stat3 in murine Natural Killer cells. -17th International Summer School on Immunology (FEBS); SEPT, 14-21; Rabac, CROATIA.

Morvan, M; Champsaur, M; Johnson, N; Sexl, V; Lanier, L (2013): Novel mouse models reveal how expression of NKG2D and its ligands on various cell subsets affects immune responses. 100th Annual Meeting of the American-Association-of-Immunologists, Honolulu, USA, MAY 03-07, 2013. J Immunol (190) 183.11-183.11.

Kenner, L; Laimer, D; Dolznig, H; Vesely, P; Kollmann, K; Schiefer, AII; Sexl, V; Staber, PB; Hoefler, G; Penninger, J; Inghirami, G; Ulrich, J (2011): New and Highly Efficient Therapy for Treatment NPM-ALK Associated Lymphomas. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, San Diego, CA, DEC 10-13, 2011. Blood (118), 21 721-721.

Nivarthi, H; Tsyrulnyk, A; Warsch, W; Wang, ZQ; Winkler, S; Kenner, L; Müller, M; Baum, C; Bunting, KD; Sexl, V; Rülicke, T; Moriggl, R (2011): Generation of a Transgenic Mouse with Inducible Constitutively Active Stat5a. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, San Diego, CA, DEC 10-13, 2011. Blood (118), 21 1456-1456.

Prchal, M; Kobolak, J; Teppner, I; Wallner, B; Semper, C; Lassing, C; Putz, EM; Dinnyes, A; Kolbe, T; Rulicke, T; Karaghiosoff, M; Sexl, V; Strobl, B; Müller, M (2011): Dissection of kinase-dependent and -independent functions of Tyk2 in immunity to infection and tumor-surveillance. 9th Joint Meeting of the International-Cytokine-Society/International-Society-for-Interferon-and-Cytokine-Research, Florence, ITALY, OCT 09-12, 2011. Cytokine (56), 1 86-86.

Prchal, M; Kobolak, J; Teppner, I; Wallner, B; Semper, C; Lassnig, C; Putz, EM; Dinnyes, A; Kolbe, T; Rülicke, T; Karaghiosoff, M; Sexl, V; Strobl, B; Müller, M (2011): Dissection of kinase-dependent and -independent functions of Tyk2 in immunity to infection and tumor-surveillance. -9th Joint Meeting of the ICS/ISICR; OKT 9-12, 2011; Florence, Italy.

Putz, EM; Zebedin-Brandl, EM; Decke, T; Prchal, M; Müller, M; Sexl, V (2011): STAT1 serine phosphorylation - putting the brakes on NK cell activity. -9th Joint Meeting of the ICS/ISICR; OKT 9-12, 2011; Florence, Italy.

Putz, EM; Zebedin-Brandl, EM; Decker, T; Prchal, M; Müller, M; Sexl, V (2011): STAT1 serine phosphorylation - Putting the brakes on NK cell activity. 9th Joint Meeting of the International-Cytokine-Society/International-Society-for-Interferon-and-Cytokine-Research, Florence, ITALY, OCT 09-12, 2011. Cytokine (56), 1 87-87.

Poster mit Vortrag

Sadovnik, I; Herrmann, H; Cerny-Reiterer, S; Warsch, W; Hoelbl, A; Blatt, K; Stefanzl, G; Hoermann, G; Herndlhofer, S; Streubel, B; Sperr, WR; Mannhalter, C; Sexl, V; Valent, P (2013): Neoplastic Stem Cells Of Ph Plus Chronic Myeloid Leukemia (Cml) Express The Alpha-Chain Of The Il-2 Receptor (Cd25). 18th Congress of the European Hematology Association, Stockholm, Sweden, June 13–16, 2013. Haematologica (98), S1 256-256.

Schuster, C; Schellack, C; Simma, O; Weisz, E; Muller, M; Sexl, V; Stoiber, D (2005): Loss of Tyk2 accelerates lymphoma formation in E mu-Myc transgenic mice. Pharmacology 2005; 75(4): 197-197.

© Veterinärmedizinische Universität Wien Hilfe und Downloads